Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANREO-PMO hemodynamic tolerance of potassium canrenoate in brain-dead organ donors
2020-003285-40Phase 2Active
- Sponsor
- CHRU Nancy
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in brain death, Cardiovascular collapse and None comparing Potassium canrenoate (Soludactone) with Placebo (0.9% sodium chloride) (2 arms). Primary endpoint: Hierarchical composite hemodynamic endpoint. Started Jul 2020; status: active.
02
Drugs
potassium canrenoate
03
Conditions
brain deathCardiovascular collapse
Beyond the preview
Go deeper on 2020-003285-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003285-40.